Sumitomo Chemical India Ltd Annual Secretarial Compliance Report for FY2026

Sumitomo Chemical India Limited has released its annual secretarial compliance report for the fiscal year ended March 31, 2026. The report, prepared by independent professionals, confirms that the company has maintained rigorous compliance standards across its corporate operations. The review covers governance, document preservation, and adherence to established policies throughout the 2025-26 financial year, ensuring transparent and ethical management practices for stakeholders.

Commitment to Corporate Governance

Sumitomo Chemical India Limited has demonstrated its ongoing commitment to transparent and ethical corporate governance. The company’s operations for the financial year ending March 31, 2026, were subjected to a thorough independent review to ensure complete alignment with all necessary procedural standards and industry best practices. The assessment validates the company’s robust internal frameworks and consistent adherence to operational transparency.

Compliance and Operational Standards

The secretarial review confirmed that the company effectively manages its internal policies, maintains functional and informative digital disclosures, and ensures that its board and committee evaluations are conducted at the start of each fiscal year. Furthermore, the company has successfully addressed prior procedural observations, demonstrating a proactive approach to operational improvements. Key areas such as related party transactions, insider trading controls, and document preservation remain in full compliance with industry standards.

Future Outlook

As of May 15, 2026, no additional non-compliance issues were identified, and the company continues to maintain a stable governance profile. By fulfilling these annual reporting requirements, Sumitomo Chemical India Limited reaffirms its dedication to maintaining high operational standards and building sustained trust with its shareholders and the broader market.

Source: BSE

Previous Article

Maruti Suzuki India Limited Commercial Production Commences at Second Kharkhoda Plant

Next Article

FDC Limited Secures US FDA Approval for Cefixime Oral Suspension